Mode
Text Size
Log in / Sign up
N/A N=526 Prevention

Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic

Sars-CoV2 · Serum; Disease

Enrolled (actual)
526
Serious AEs
Results posted
Jan 2024
Primary outcome: Primary: Rate of Positive Serological Immune Status to a Previous Infection by the SARS-CoV-2 Virus at Inclusion — 18 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
PRO-SERO-COV (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Institut Bergonié
Primary completion
Jan 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate of Positive Serological Immune Status to a Previous Infection by the SARS-CoV-2 Virus at Inclusion
18
SECONDARY
Rate of Positive Serological Immune Status to a Previous Infection by the SARS-CoV-2 Virus at 3 Months
31
SECONDARY
Rate of Positive Serological Immune Status to a Previous Infection by the SARS-CoV-2 Virus at 12 Months
46
SECONDARY
Number of Health Care Workers With Active COVID-19 Infection
0; 0; 0
SECONDARY
Number of Health Care Workers With Symptoms of Anxiety at 0 Months (Inclusion)
36
SECONDARY
Number of Health Care Workers With Symptoms of Anxiety at 3 Months
49
SECONDARY
Number of Health Care Workers With Symptoms of Anxiety at 12 Months
30

Summary

The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue. Knowing the evolution of this response over time in this population can help answer outstanding questions. The PRO-SERO-COV study is a seroprevalence study of caregivers working in the hospital sector with a follow-up at 3 months and 12 months. The objective is to evaluate and monitor at 3 and 12 months the serological immune status to an infection by the SARS-CoV-2 virus in active volunteer professionals working at the Institut Bergonié with different types of exposure: healthcare professionals and professionals in other services.

Eligibility Criteria

Inclusion Criteria

  • Adult 18 years-old and older.
  • Person in employment (on fixed-term or permanent contracts) since (at least) March 17th, 2020, the date of national implementation of containment measures in response to the COVID-19 pandemic.
  • Signed informed consent.
  • Person affiliated to a French social security regimen in accordance with Article 1121-11 of the French Public Health Code).

Exclusion Criteria

  • Report of known active SARS-CoV-2 infection within 10 days prior to the date of signing the consent. Known active SARS-CoV-2 infection is defined as a positive result on a diagnostic RT-PCR test.
  • Presence of known symptoms suggestive of COVID-19 within 10 days prior to the date of signing consent: fever, fatigue, dry cough, shortness of breath, loss of taste and/or smell, headache, body aches, aches and pains, conjunctivitis or colds, digestive disorders (vomiting, diarrhea).
  • A person who is unable to follow and comply with research procedures due to geographical, social or psychological reasons.
  • Pregnant or breastfeeding woman.
  • Person deprived of their liberty, incapable or incapable of giving their consent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04426006). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search